Transarterial chemoembolization (TACE) in patients with unresectable diffuse vs. focal hepatocellular carcinoma (HCC).

被引：1
|
作者：
Pan, SH [1 ]
Ramirez, C [1 ]
Hoffman, A [1 ]
Sher, L [1 ]
Rojter, S [1 ]
Lopez, RR [1 ]
机构：
[1] St Vincents Med Ctr, Los Angeles, CA USA
来源：
GASTROENTEROLOGY | 2000年 / 118卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(00)86110-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1136
引用
收藏
页码：A991 / A991
页数：1
相关论文
共 50 条
  • [1] Transarterial chemoembolization in patients with unresectable diffuse vs. focal hepatocellular carcinoma.
    Pan, SH
    Ramirez, C
    Hoffman, A
    Linda, S
    Rojter, S
    Lopez, RR
    HEPATOLOGY, 1999, 30 (04) : 683A - 683A
  • [2] Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma
    Lopez, RR
    Pan, SH
    Hoffman, AL
    Ramirez, C
    Rojter, SE
    Ramos, H
    McMonigle, M
    Lois, J
    ARCHIVES OF SURGERY, 2002, 137 (06) : 653 - 657
  • [3] Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma - Comment
    Talamonti, MS
    O'Connell, TX
    Vauthey, JN
    Lopez
    ARCHIVES OF SURGERY, 2002, 137 (06) : 657 - 658
  • [4] Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma
    Zhao, Shoujie
    Dou, Weijia
    Fan, Qingling
    Hu, Jie
    Li, Huichen
    Zhang, Xiangnan
    Zhang, Qian
    Liu, Lei
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (09)
  • [5] Transarterial chemoembolization (TACE) plus apatinib vs. TACE alone for hepatocellular carcinoma
    Li, Ningjie
    Yang, Ping
    Fang, Jun
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (09)
  • [6] Inflammatory Markers are Associated with Outcome in Patients with Unresectable Hepatocellular Carcinoma (HCC) undergoing Transarterial Chemoembolization (TACE)
    McNally, M. E.
    Martinez, A.
    Malhotra, L.
    Bloomston, M.
    Schmidt, C. R.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S33 - S33
  • [7] TRANSARTERIAL CHEMOEMBOLIZATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) WITH DRUG ELUTING BEADS (DEB-TACE)
    Campo, N.
    Gazzo, P.
    Azzola, E.
    Ivaldi, D.
    Lupo, S.
    Magnolia, M.
    Milazzo, S.
    Rainisio, C.
    Barbera, G.
    Testa, R.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S90 - S90
  • [8] TRANSARTERIAL CHEMOEMBOLIZATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) WITH DRUG ELUTING BEADS (DEB-TACE)
    Campo, N.
    Gazzo, P.
    Azzola, E.
    Lupo, S.
    Ivaldi, D.
    Barbera, G.
    Magnolia, M.
    Milazzo, S.
    Rainisio, C.
    Testa, R.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S153 - S153
  • [9] Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).
    Prins, Petra
    Singh, Bhavana P.
    Armstrong, Samantha Ann
    He, Aiwu Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Thalidomide (Thal) tolerance in patients treated with transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)
    Goldenberg, A
    Volm, M
    Hochster, H
    Muggia, F
    Rosen, R
    Teperman, L
    Morgan, G
    Schwartz, J
    Sung, M
    Wadler, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 376S - 376S
12345